Roche Forced To Wait By FDA For SC Tecentriq Okay
Seven-Minute Injection Recently Approved In UK
The Swiss major’s partner Halozyme has revealed that the US launch for the subcutaneous version of the checkpoint inhibitor Tecentriq will be put back until 2024 following questions from the Food and Drug Administration about manufacturing processes.
You may also be interested in...
A subcutaneous version of Ocrevus is as effective as the intravenous form of Roche's biggest seller, and could boost access of the multiple sclerosis drug where access to intravenous clinics is problematic.
The US approval of a more convenient formulation of its myasthenia gravis therapy, Vyvgart, should cement its market position as well as change the definition of what being "well-controlled means for patients", Argenx hopes.
The Roche affiliate hopes to bring subcutaneous Tecentriq to market, offering patient and clinician advantages while also beating Merck’s Keytruda and Bristol’s Opdivo to the finish line